By Will Feuer Omeros said it is discontinuing its late-stage clinical trial evaluating its narsoplimab drug for the treatment of immunoglobulin A nephropathy.
By Will Feuer Shares of Omeros were cut nearly in half after the company said it is discontinuing its late-stage clinical trial evaluating its narsoplimab.